Stockreport

NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook [Yahoo! Finance]

Neuropace, Inc.  (NPCE) 
PDF 2026 guidance assumes 20% to 22% growth in core RNS revenue from existing indications, excluding any contribution from idiopathic generalized epilepsy (IGE)-- --IGE i [Read more]